Category: Cognitive Disorders (non-PD)
Objective: The objective of this study was to assess the cost effectiveness of biomarkers used for early diagnosis of dementia disorders.
Background: Dementia remains a substantial public health burden with extensive clinical and socioeconomic impact. The early and specific diagnosis may help in guiding therapy and delay the progression of disease severity. The Economic evaluations can ensure that the inadequate available resources are allocated as efficiently as possible, helping health care decision makers to make informed decision.
Method: A systematic literature search was performed in PubMed and CEA Registry with pairing relevant keywords to identify English language articles for last 10 years. The eligible studies determine the cost-effectiveness of the use of biomarker for early diagnosis of dementia disorders. Study characteristics, methods and outcomes were critically assessed. The Quality of Health Economic Studies (QHES) instrument (total score ranges from 0-100) was used for quality assessment of included studies.
Results: Majority of studies reported the biomarkers in CSF was examined in order to early diagnosis and screening for Alzheimer’s disease (AD). Four studies reported Societal perspective, and others are reported health care (n=3) and respective country health system (French health technology assessment). All but two studies were funded by the industry and the studies did not indicate favorable cost effectiveness based on funding. The studies were used simulation model (n=3) and decision tree model (n=3) and Markov model (n=2), for their analyses. Although all studies performed sensitivity analyses to test the robustness of their results. The overall mean QHES score was 79.12. The scores ranged from 69 to 87. Most of the studies were scored between 75 and 100 (high quality). According to the QHES, the quality of the studies was seeming to be sufficient.
Conclusion: Majority of the studies reported biomarkers used for screening is cost-effective. Moreover, further economic evaluations studies as well as good quality effectiveness studies needed for health care intervention and decision making.
To cite this abstract in AMA style:M. Azharuddin, M. Sharma. Critical appraisal of economic evaluation of biomarkers used for screening dementia [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/critical-appraisal-of-economic-evaluation-of-biomarkers-used-for-screening-dementia/. Accessed March 4, 2024.
« Back to 2022 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/critical-appraisal-of-economic-evaluation-of-biomarkers-used-for-screening-dementia/